Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therap...
FY 2025
Mar 19, 2026
Q4 2025
Q3 2025
Nov 7, 2025
Q2 2025
Aug 4, 2025
Q1 2025
May 12, 2025